Printer Friendly

U.S. BIOSCIENCE NAMES BROWN, VOGEL TO SENIOR MANAGEMENT POSTS

 U.S. BIOSCIENCE NAMES BROWN, VOGEL TO SENIOR MANAGEMENT POSTS
 WEST CONSHOHOCKEN, Pa., May 4 /PRNewswire/ -- U.S. Bioscience Inc. (AMEX: UBS) today named Donald O. Brown senior vice president, pharmaceutical operations, and Richard C. Vogel vice president and general manager, Europe. Both men will report to Russell C. McLauchlan, newly appointed president and chief operating officer of U.S. Bioscience, a pharmaceutical company specializing in new treatments for cancer and related diseases.
 Brown, 49, will have responsibility for the consolidation and direction of manufacturing, product development and related analytical activities which are currently dependent on outside contractors. He was most recently group director for international quality control and quality assurance at Alcon Laboratories Inc. where previously he held manufacturing positions in the United States and Europe. Prior to that, he served in senior production and engineering posts with the Mead Johnson unit of Bristol-Myers, a forerunner of the Bristol-Myers Squibb Co.
 Based in Europe, Vogel, 49, will be responsible for obtaining broad European distribution for U.S. Bioscience products as they are approved by regulatory authorities. His duties will include the establishment of sales, marketing and general management functions in the major European markets. He was formerly vice president of worldwide sales and marketing for Vestar Inc., and previously held a number of sales management posts in Europe for the International Medical Division of American Cyanamid Co.
 "These appointments underscore our commitment to advancing U.S. Bioscience from a developer of drugs to a fully integrated pharmaceutical company able to manufacture and commercialize our compounds," said Philip S. Schein, M.D., chairman and chief executive officer. "With the recent appointment of Russell McLauchlan as president and chief executive officer these new posts provide senior management with the structure required to effectively pursue this goal."
 Based in West Conshohocken, U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life for patients with cancer and allied diseases. The company's portfolio includes a broad spectrum of cancer drugs, including four products in the late stages of development. One compound, altretamine, is marketed under the Hexalen(R) in the United States.
 -0- 5/4/92
 /CONTACT: Robert I. Kriebel of U.S. Bioscience, 215-832-4503/
 (UBS) CO: U.S. Bioscience ST: California IN: MTC SU: PER


TS-JL -- SJ002 -- 5846 05/04/92 08:58 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 4, 1992
Words:394
Previous Article:TV GUIDE AND LIBERTY MEDIA TO LAUNCH INTERACTIVE ELECTRONIC PROGRAM GUIDE
Next Article:CORNING KERAMIK ANNOUNCES MAJOR MANUFACTURING EXPANSION


Related Articles
U.S. BIOSCIENCE NAMES RUSSELL MCLAUCHLAN PRESIDENT
/C O R R E C T I O N -- U.S. BIOSCIENCE/
DISTINGUISHED ONCOLOGIST JOINS BOARD OF DIRECTORS OF U.S. BIOSCIENCE
U.S. BIOSCIENCE REJECTS INACCURATE REPORTS ON ETHYOL(R)
U.S. BIOSCIENCE REJECTS INACCURATE REPORTS ON ETHYOL(R)
U.S. BIOSCIENCE NAMES AYER-PTASZEK VICE PRESIDENT - MARKETING
Mosaic Technologies Appoints Michael E. Woehler as Its New President and Chief Executive Officer.
Delaware Investments Appoints New Co-Managers to Delaware Investments Dividend and Income Fund, Inc. and Delaware Investments Global Dividend and...
DNA Bioscience Hires Global Healthcare Expert to New Role of CEO.
Ventria Expands Lactoferrin Production.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters